Cursor and Notification Center

Johns Hopkins University and Bloomberg Philanthropies today announced the launch of a $150 million effort to directly address historic underrepresentation in science, technology, engineering, and math fields, and to prepare a new, more diverse generation of researchers and scholars to assume leading roles in tackling some of the world's greatest challenges.

 

Emmes Logo

ROCKVILLE, Md., May 12, 2021 /PRNewswire/ -- Emmes (the "Company"), a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation and a portfolio company of Behrman Capital, today announced that it has acquired Orphan Reach, a CRO specialized in clinical research related to rare diseases. Financial terms of the transaction were not disclosed.

 

JLabs Logo

Set on the historic Walter Reed Army Medical Center, the Children’s National Research & Innovation Campus will be a one-of-kind innovation hub. The nearly 12-acre campus will house leading entrepreneurs, thinkers, innovators and experts aiming to improve the health and well-being of patients around the world. Johnson & Johnson Innovation – JLABS @ Washington, DC will occupy a 32,000—square foot facility open to biotech, medical device, consumer and health technology start-ups aiming to develop new medicines, medical devices, precision diagnostics and health tech applications. Additionally, in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, JLABS @ Washington, DC will be the hub for BLUE KNIGHT. Blue Knight is a collaboration dedicated to and aimed at anticipating health security threats, activating the global innovation community, and amplifying technological advancements to prepare for and respond to our rapidly evolving global health environment. We look forward to the opening of JLABS @ Washington, DC in collaboration with our partners at Children’s National Hospital and BARDA to support innovation for patients.

 

Adaptive Phage Therapeutics

GAITHERSBURG, Md.--(BUSINESS WIRE)--Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company has closed a $40.75 million Series B investment round led by Deerfield Management Company. Also joining the Series B round are existing investor Mayo Clinic and an additional undisclosed institutional investor. Proceeds of this financing will be used to accelerate clinical development of PhageBank™ phage therapies, as well as for general corporate purposes.

 

ellume logo

By 2022, Frederick County will see an estimated 1,500 new jobs after diagnostics solutions company Ellume moves in.

The Australian-based company, which makes at-home COVID-19 tests, is set to open its first U.S. manufacturing facility in Frederick, county officials announced Monday.

The 180,000-square-foot facility in the Progress Labs Corporate Park off Md. 85 will be home to the plant.

 

NewImage

Ellume, an Australian company specializing in diagnostics solutions for infectious diseases, is set to open its first U.S. manufacturing facility in Frederick, county officials announced Monday.

The 180,000-square-foot facility in the Progress Labs Corporate Park off Md. 85 will serve as a manufacturing plant, where Ellume will make at-home COVID-19 tests and bring an estimated 1,500 jobs to Frederick County by 2022. 

“This is great news for Frederick County,” Frederick County Executive Jan Gardner said in a news release. “Ellume is on the cutting edge, making products that will help the world to overcome this health pandemic. We are excited to welcome Ellume to our thriving life science and biopharma family."

Image: Courtesy photo via ellumehealth.com

Maryland is Open for Business Make Your Move

Maryland’s biohealth boom continues, with Australian bio company Ellume announcing its entrance in the United States. Ellume, a Queensland digital diagnostics company, recently signed a $231.8 million agreement with the federal government to accelerate domestic production of its COVID-19 home tests. The company will establish a manufacturing facility in Maryland, its first in the United States, to accommodate the demand for its products targeting infectious diseases. 

 

natsumi 200x200

ROCKVILLE, MARYLAND, May 10, 2021 BioHealth Innovation Inc. (BHI) announces the addition of Dr. Natsumi Takahashi-Vitiello, PhD in the role of Analyst. In her new position, Dr. Takahashi-Vitiello will assist the Entrepreneurs-in-Residence (EIR) Program at BHI in the evaluation of early-stage technologies, strategic planning for start-up companies, and identification/developmental strategies of new venture opportunities.

 “I am pleased to welcome Dr. Natsumi Takahashi-Vitiello to the BHI family,” said Richard Bendis, BHI President, and CEO. “Her biohealth business experience and scientific background will support the BHI clients in their commercialization and fund-raising activities.”

AnneandRich

Rich Bendis welcomes Dr. Anne Khademian, Executive Director, The Universities at Shady Grove, on BioTalk to discuss Higher Ed in Montgomery County, their Biomedical Sciences and Engineering (BSE) facility, and Strategic Partnerships.

Listen now on Apple https://apple.co/3xYZG9P , Google https://bit.ly/3eyQ6mm, Spotify https://spoti.fi/3o4vztl, and TuneIn https://bit.ly/2SHbI7N.

Dr. Anne Khademian was named to serve as the Universities at Shady Grove’s third executive director in October 2020, following a nationwide search and her appointment to the post by Dr. Jay Perman, Chancellor of the University System of Maryland. As executive director of USG – a regional higher education center of USM in Montgomery County, with programs from nine universities on one campus – Dr. Khademian also holds the title of Associate Vice Chancellor for Academic Affairs for USM.

AZIYO Logo

Aziyo Biologics Inc. is executing growth plans it established ahead of its initial public offering last fall — and starting to see results.

The regenerative medicine firm, which started trading on the Nasdaq in October, saw a first-quarter revenue increase year over year “despite some ongoing Covid-related headwinds,” President and CEO Ron Lloyd said in a statement this week.

 

University of Maryland Logo

The University of Maryland will launch a new business development arm to nurture quantum-focused startups, President Darryll J. Pines announced last night at an event honoring the institution’s inventions, startup, mentor and student entrepreneurs of the year.

The Quantum Startup Foundry will support new businesses in the quantum technology field, which Pines said stands “poised to disrupt everything from cybersecurity and energy, to medical discoveries and the financial field.” It will be created through an initial $25 million investment from the university’s newly established Discovery Fund, with key funding from the state of Maryland.

 

Notification Center

HOLON, Israel, May 10, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has expanded its research collaboration with Johns Hopkins University to include studies investigating the biology of a novel myeloid target that was computationally-discovered by Compugen. Initial preclinical studies demonstrate the potential of this target to serve as a novel myeloid immunomodulator, with significant tumor growth inhibition observed upon genetic deletion in in-vivo studies.

 

Notification Center

The AIM-HI Accelerator Fund’s Women’s Venture Competition is a first-of-its-kind program that provides funding, coaching and networking opportunities to women-led oncology start-ups. Subject to due diligence and negotiation, the winning company of 2021 Women’s Venture Competition will receive a total of $1 million in investment from AIM-HI and co-investors. Click here to download the flyer!

 

NewImage

COLUMBIA, Md. (May 10, 2021)—The Maryland Stem Cell Research Commission has approved funding to its second-round of 2021 recipients for a total of $6,052,901. The Commission has also appointed Amritha Jaishankar, Ph.D., the current MSCRF Director - Programs & Strategic Alliances, to succeed Dan Gincel, Ph.D., as Executive Director of the MSCRF, effective May 14, 2021.

“We thank Dr. Gincel for his leadership and many contributions to the MSCRF over the course of his 14 years as Executive Director, during which he consistently challenged us to grow and evolve to meet the needs of the Maryland stem cell community, and we are delighted that Dr. Jaishankar will lead the MSCRF through its next chapter,” said Dr. Debra Mathews, Chair of the Commission. “Dr. Jaishankar’s leadership, dedication, and tremendous work with the MSCRF and our stem cell community over past few years make her the ideal person to take us forward.”

 

NewImage

Now we are in the final phase of completing the last work in BioPartner 5. The second floor is ready to be used. Today, MIMETAS received the keys tot their brand new floor in BioPartner 5. We would like to give Mimetas a warm welcome!